Mepicain (Mepivacaine Hydrochloride)

Mepicain is a local anesthetic used to achieve temporary loss of sensation in specific tissues during minor procedures.

• Dental procedures: provides analgesia for extractions, restorations and periodontal surgery.
• Minor surgical procedures: facilitates anesthesia for skin suturing, biopsy and minor excisions.
• Diagnostic procedures requiring local anesthesia: enables patient comfort during endoscopy, catheter placement and similar interventions.

• Mepivacaine Hydrochloride reversibly blocks voltage‑gated sodium channels in neuronal membranes, preventing the initiation and propagation of action potentials. By stabilizing the neuronal membrane, it inhibits nerve impulse transmission, resulting in a localized loss of sensation without affecting consciousness.

Mepicain may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Transient tingling or numbness at the injection site
• Mild dizziness or light‑headedness
• Temporary increase in heart rate
• Mild nausea or vomiting
• Localized swelling or erythema

Serious or Rare Side Effects

• Allergic reaction (rash, pruritus, bronchospasm, anaphylaxis)
• Central nervous system toxicity (seizures, tremors, loss of consciousness)
• Cardiovascular toxicity (arrhythmias, hypotension, cardiac arrest)
• Methemoglobinemia
• Persistent paresthesia or nerve injury

Before using Mepicain, clinicians should assess patient history and monitor for potential complications.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular status: avoid in patients with severe conduction disorders or uncontrolled arrhythmias.
• Neurological conditions: use cautiously in patients with epilepsy or other seizure disorders.
• Drug interactions: review concomitant medications that may affect cardiac or CNS function.
• Pregnancy and lactation: consider risk‑benefit ratio; use only if clearly needed.
• Store below 25°C: keep in the original container, protect from light and moisture.

Mepicain can interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid)

• Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide): may potentiate cardiotoxicity.
• Monoamine oxidase inhibitors (MAOIs): increase risk of severe hypertension.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may exacerbate bradycardia.
• CNS depressants (e.g., benzodiazepines, opioids): enhance sedation and respiratory depression.
• Other local anesthetics: cumulative toxicity risk.
• Diuretics: may alter plasma protein binding, affecting drug levels.